UCB

Stock Price
206.90
Daily Change
2.30 1.12%
Monthly
13.18%
Yearly
28.99%
Q3 Forecast
205.56

Peers Price Chg Day Year Date
Alcon AG 64.08 0.62 0.98% -19.15% Sep/05
Almirall 10.96 -0.16 -1.44% 27.89% Sep/05
Amarin 15.33 0.30 2.00% 27.64% Sep/05
argenx SE 639.80 8.40 1.33% 31.21% Sep/05
AstraZeneca 12,090.00 -98.00 -0.80% -4.89% Sep/06
Bayer 28.16 -0.42 -1.47% -1.83% Sep/06
Genmab 1,751.50 6.50 0.37% -5.83% Sep/05
Galapagos 28.44 1.84 6.92% 11.53% Sep/06
GRIFOLS 12.30 0.02 0.16% 32.17% Sep/05
GlaxoSmithKline 1,476.00 7.00 0.48% -10.63% Sep/05
Hikma Pharmaceutical 1,720.00 -3.00 -0.17% -12.07% Sep/05
Lonza 577.40 -0.80 -0.14% 7.68% Sep/05
Merck 109.55 1.05 0.97% -35.52% Sep/06
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Orion 65.90 -1.10 -1.64% 36.67% Sep/05
Recordati 54.05 -0.25 -0.46% 5.16% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
UCB 206.90 2.30 1.12% 28.99% Sep/05
Unibail Rodamco 87.58 1.30 1.51% 15.72% Sep/05

Indexes Price Day Year Date
BE20 4769 23.50 0.50% 14.34% Sep/05
EU100 1582 -4.83 -0.30% 9.89% Sep/05
EU600 549 -0.88 -0.16% 8.42% Sep/05

UCB traded at 206.90 this Friday September 5th, increasing 2.30 or 1.12 percent since the previous trading session. Looking back, over the last four weeks, UCB gained 13.18 percent. Over the last 12 months, its price rose by 28.99 percent. Looking ahead, we forecast UCB to be priced at 205.56 by the end of this quarter and at 201.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.